Amlexanox is a specific inhibitor of IKKε and TBK1. Amlexanox blocked IKKε activity with a half maximal inhibitory concentration of approximately 1–2 μM. Amlexanox increased phosphorylation of TBK1 on Ser172 in 3T3-L1 adipocytes. Mice treated with amlexanox concurrently with HFD had improved glucose tolerance, with an approximate 30–40% reduction in the area under the curve for glucose. After a 100mg dose of 5% amlexanox topical paste, applied directly to the lesion, the maximum serum concentration of the drug was 120 ng/mL, which was achieved 2.4 hours after application.
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
Amlexanox for the treatment of recurrent aphthous ulcers.
Bell J. Clin Drug Investig. 2005;25(9):555-66. PMID: 17532700.
|Related IκB/IKK Products|
LY2409881 is a novel selective inhibitor of IKK2 with IC50 of 30 nM; IC50 for IKK1 and other common kinases is at least one log higher.
PS-1145 is a specific IKK inhibitor with IC50 of 88 nM.
Bardoxolone is an IKK inhibitor, showing potent proapoptotic and anti-inflammatory activities; Also a potent Nrf2 activator and nuclear factor-κB (NF-κB) inhibitor.
PHA-408 is a highly selective and ATP-competitive IKK-2 inhibitor with IC50 of 40 nM.
IMD-0354 is an IKKβ inhibitor and blocks IκBα phosphorylation in NF-κB pathway.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.